COMP <GO>
CI vs MRK // NET PROFIT MARGIN
The Cigna Group (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CI 4
— MRK 11
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $298.23 (-0.06%) • MKT CAP: $78.85B
net-margins
2.20%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CI VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CI | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.80% | 74.80% | -53.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.80% | 20.70% | -11.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 15.3x | -9.20 | CI | /valuation <GO> |
| Free Cash Flow Yield | -3.51% | 3.42% | -6.93 | MRK | /fcf-yield <GO> |
| Operating Margin | 3.30% | 34.30% | -31.00 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 2.20% | 28.10% | -25.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 1.30% | +9.90 | CI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.04% | 2.26% | -0.22 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.70 | 5.19 | -2.49 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.60% | +0.70 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.6 | 56.9 | -1.24 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.92 | +0.20 | CI | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.3x | 18.4x | -6.10 | CI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $78.85B | $361.02B | -$282.17B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CI REV | MRK REV | CI GROSS % | MRK GROSS % | CI FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $274.90B | $65.01B | 21.8% | 74.8% | -$2.77B | $12.36B |
| FY 2024 | $247.12B | $64.17B | 26.1% | 76.3% | -$757.4M | $18.10B |
| FY 2023 | $195.26B | $60.12B | 44.0% | 44.0% | $3.03B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CI // BETA 1.12
MRK // BETA 0.92